306P - Plasma cell leukemia – review of 40 cases from India

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Leukaemia
Presenter Geetha Narayanan
Citation Annals of Oncology (2015) 26 (suppl_9): 85-92. 10.1093/annonc/mdv526
Authors G. Narayanan, A. Surendran, S.G. Nair, L. V Soman, P. N Purushothaman
  • Medical Oncology, Regional Cancer Centre Thiruvananthapuram/Trivandrum, 695011 - Thiruvananthapuram (Trivandrum)/IN

Abstract

Aim/Background

To study the clinical presentation, treatment and survival of patients with plasma cell leukemia.

Methods

This is a retrospective analysis of case records of patients with plasma cell leukemia treated in the department of medical oncology at Regional Cancer Centre, Trivandrum, India, during the period 1999-2013.

Results

Forty patients with plasma cell leukemia was seen during the period 1999- 2013. There were 23 males and 17 females. The median age was 56 years. The main symptoms at presentation were pallor, fever, pain, recurrent infections. The median duration of symptom was 2 months. Twenty two patients had a Hemoglobin less than 8gm/dl, and 20 had a platelet count less than 50000/mm3. Serum creatinine was elevated in 20 cases and hypercalcemia was present in 8 cases. IgG was the commonst subtype of M protein. ß microglobuin was elevated in 13 patients. Only 30 patients received chemotherapy which consisted of thaldex in 9, VAD in 7, Bortezomib containing regimen in 5, vincristine, cyclophosphamide and steroid in 4 and high dose dexona in 3. One patient underwent high dose melphalan followed by autologous stem cell transplant. Six patients were alive at 2 years. Among the 5 patients who received bortezomib, 3 were alive at 2 years (60%).

Conclusions

Plasma cell leukemia is a disease of the male, with median age at onset of 56 years. The prognosis is very poor with 2 year overall survival of 15%. Bortezomib containing regimens are very effective in plasma cell leukemia with 60% alive at 2 years.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.